Standard Biotools (LAB) Net Income towards Common Stockholders Growth (1y) (2011 - 2026)
Standard Biotools (LAB) Net Income towards Common Stockholders Growth (1y) (2011 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 198.93 Bn | 193.33 Bn | 7.27 Bn | -47.84% |
| 2 | Stryker | 128.56 Bn | 125.08 Bn | 4.50 Bn | 44.34% |
| 3 | Medtronic | 119.26 Bn | 110.04 Bn | 6.41 Bn | 18.55% |
| 4 | Boston Scientific | 73.35 Bn | 72.81 Bn | 3.85 Bn | 13.80% |
| 5 | Edwards Lifesciences | 52.06 Bn | 47.81 Bn | 1.35 Bn | -27.18% |
| 6 | Dexcom | 34.55 Bn | 32.61 Bn | 830.00 Mn | 38.54% |
| 7 | GE HealthCare Technologies | 34.05 Bn | 31.94 Bn | 2.18 Bn | 14.80% |
| 8 | Koninklijke Philips | 26.39 Bn | 23.07 Bn | 4.55 Bn | 73.85% |
| 9 | Steris | 23.15 Bn | 22.67 Bn | 684.20 Mn | 12.92% |
| 10 | Standard Biotools | 254.39 Mn | -222.33 Mn | 10.54 Mn | 20.00% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 84.36% |
| Mar 31, 2026 | 5,420.84% |
| Dec 31, 2025 | -115.63% |
| Sep 30, 2025 | -58.25% |
| Jun 30, 2025 | 30.54% |
| Mar 31, 2025 | 91.71% |
| Dec 31, 2024 | -1.78% |
| Sep 30, 2024 | -4.14% |
| Jun 30, 2024 | -49.33% |
| Mar 31, 2024 | -90.76% |
| Dec 31, 2023 | -90.78% |
| Sep 30, 2023 | 28.47% |
| Jun 30, 2023 | 73.19% |
| Mar 31, 2023 | 77.92% |
| Sep 30, 2022 | 40.93% |
| Jun 30, 2022 | -76.77% |
| Mar 31, 2022 | -305.96% |
| Sep 30, 2021 | -724.51% |
| Jun 30, 2021 | -176.24% |
| Mar 31, 2021 | -17.74% |